bioAffinity Technologies Appoints Nationally Recognized Experts to Medical and Scientific Advisory Board

summarizeSummary

bioAffinity Technologies announced the appointment of three nationally recognized experts in pulmonary medicine and lung cancer to its Medical and Scientific Advisory Board, aiming to strengthen guidance for its CyPath Lung diagnostic test.

check_boxKey Events

• New Advisory Board Appointments

  David Ost, MD, MPH, Daniel Sterman, MD, and J. Scott Ferguson, MD, have been appointed to the Medical and Scientific Advisory Board.

• Expertise in Pulmonary and Lung Cancer

  The new members are nationally recognized leaders in interventional pulmonology, thoracic oncology, critical care, and advanced diagnostic techniques for lung cancer.

• Strategic Alignment for CyPath Lung

  The appointments aim to provide independent guidance on strategic priorities, including growing the adoption of the company's noninvasive CyPath Lung diagnostic test.

auto_awesomeAnalysis

bioAffinity Technologies, a biotechnology company focused on lung cancer diagnostics, has significantly strengthened its Medical and Scientific Advisory Board with the appointment of three highly respected experts in pulmonary medicine and lung cancer. These appointments are crucial for the company as it seeks to integrate its noninvasive CyPath Lung diagnostic test into the standard of care. The expertise of Drs. Ost, Sterman, and Ferguson in interventional pulmonology, thoracic oncology, and advanced diagnostic techniques will provide invaluable guidance for the clinical, scientific, and commercial priorities of CyPath Lung, potentially accelerating its adoption and market penetration.